solo para uso en investigación
Cat. No.S2012
| Líneas celulares | Tipo de ensayo | Concentración | Tiempo de incubación | Formulación | Descripción de la actividad | PMID |
|---|---|---|---|---|---|---|
| LAN1 | Growth inhibition assay | 72 hrs | Growth inhibition of human LAN1 cells incubated for 72 hrs by MTS assay, GI50=3.9μM | 23116147 | ||
| Jurkat | Growth inhibition assay | 72 hrs | Growth inhibition of human Jurkat cells incubated for 72 hrs by MTS assay, GI50=11μM | 23116147 | ||
| NB-1 | Growth inhibition assay | 72 hrs | Growth inhibition of human NB-1 cells incubated for 72 hrs by MTS assay, GI50=14μM | 23116147 | ||
| MT2 | Growth inhibition assay | 72 hrs | Growth inhibition of human MT2 cells incubated for 72 hrs by MTS assay, GI50=15μM | 23116147 | ||
| MT4 | Growth inhibition assay | 72 hrs | Growth inhibition of human MT4 cells incubated for 72 hrs by MTS assay, GI50=25μM | 23116147 | ||
| Huh7 | Antiviral assay | 3 days | Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay, EC50=1.8μM | 25490700 | ||
| HuH7 | Cytotoxicity assay | 3 days | Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay, CC50=11μM | 25490700 | ||
| Sf9 | Function assay | 5 mins | Inhibition of recombinant full-length human C-terminal FLAG-His-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using Boc-L-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 35 mins by fluoresce, IC50=3.8μM | 28835796 | ||
| Sf9 | Function assay | 5 mins | Inhibition of recombinant human full-length C-terminal His-tagged HDAC3 (395 to 489 residues)/human NCOR2 expressed in baculovirus infected Sf9 insect cells using Boc-L-Lys(Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition measured, IC50=7.1μM | 28835796 | ||
| Sf9 | Function assay | 5 mins | Inhibition of recombinant human full-length C-terminal His-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-L-Lys(Ac)-AMC as substrate preincubated for 5 mins followed by substrate addition measured after 35 mins by fluorescence assay, IC50=31μM | 28835796 | ||
| SH-SY5Y | Cytotoxicity assay | Cytotoxicity against human SH-SY5Y cells expressing TP53 by CellTiter96 AQueous one solution cell proliferation assay | 28835796 | |||
| IMR5 | Cytotoxicity assay | Cytotoxicity against human IMR5 cells expressing TP53 by CellTiter96 AQueous one solution cell proliferation assay | 28835796 | |||
| SK-N-AS | Cytotoxicity assay | Cytotoxicity against human SK-N-AS cells expressing TP53 mutation by CellTiter96 AQueous one solution cell proliferation assay | 28835796 | |||
| Kelly | Cytotoxicity assay | Cytotoxicity against human Kelly cells expressing TP53 mutation by CellTiter96 AQueous one solution cell proliferation assay | 28835796 | |||
| BE(2)-C | Cytotoxicity assay | 72 hrs | Cytotoxicity against human BE(2)-C cells assessed as reduction in cell viability by measuring metabolic activity after 72 hrs by WST-8 assay, IC50=19.9μM | 29190092 | ||
| Sf9 | Function assay | 90 mins | Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC1 expressed in fall armyworm Sf9 cells using fluorogenic ZMAL as substrate after 90 mins by fluorimetric analysis, IC50=28.3μM | 29190092 | ||
| Sf9 | Function assay | 90 mins | Inhibition of recombinant human full length HDAC6 expressed in fall armyworm Sf9 cells using fluorogenic ZMAL as substrate after 90 mins by fluorimetric analysis, IC50=48.2μM | 29190092 | ||
| BE(2)-C | Function assay | 6 uM | 72 hrs | Inhibition of HDAC8 in human BE(2)-C cells assessed as upregulation of p21/CDKN1 gene expression at 6 uM after 72 hrs by RT-PCR analysis relative to control | 29190092 | |
| BE(2)-C | Function assay | 6 uM | 72 hrs | Inhibition of HDAC8 in human BE(2)-C cells assessed as upregulation of TrkA/NTRK1 gene expression at 6 uM after 72 hrs by RT-PCR analysis relative to control | 29190092 | |
| BE(2)-C | Function assay | 6 uM | 72 hrs | Inhibition of HDAC8 in human BE(2)-C cells assessed as upregulation of TH gene expression at 6 uM after 72 hrs by RT-PCR analysis relative to control | 29190092 | |
| BE(2)-C | Function assay | 6 uM | 6 days | Induction of outgrowth of neurofilament positive neutrite-like structures in human BE(2)-C cells at 6 uM after 6 days by DAPI-staining based microscopic analysis | 29190092 | |
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | |||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | |||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| Jurkat | Antiproliferative assay | Antiproliferative activity against human Jurkat cells by alamar blue assay, GI50=2.4μM | 29505935 | |||
| HUT78 | Antiproliferative assay | Antiproliferative activity against human HUT78 cells by alamar blue assay, GI50=2.4μM | 29505935 | |||
| HSB2 | Antiproliferative assay | Antiproliferative activity against human HSB2 cells by alamar blue assay, GI50=2.4μM | 29505935 | |||
| MOLT4 | Antiproliferative assay | Antiproliferative activity against human MOLT4 cells by alamar blue assay, GI50=2.4μM | 29505935 | |||
| Jurkat | Antiproliferative assay | 48 hrs | Antiproliferative activity against human Jurkat cells after 48 hrs by MTT assay, IC50=4.5μM | 29533873 | ||
| MOLT4 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay, IC50=9.4μM | 29533873 | ||
| HEL | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HEL cells after 48 hrs by MTT assay, IC50=10.8μM | 29533873 | ||
| SK-N-BE(2) | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SK-N-BE(2) cells after 48 hrs by MTT assay, IC50=16.9μM | 29533873 | ||
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50=19.2μM | 29533873 | ||
| K562 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human K562 cells after 72 hrs by MTS assay, GI50=2.01μM | 30004697 | ||
| K562R | Antiproliferative assay | 72 hrs | Antiproliferative activity against human K562R cells after 72 hrs by MTS assay, GI50=2.2μM | 30004697 | ||
| HCT116 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay, GI50=2.64μM | 30004697 | ||
| PC3 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay, GI50=2.66μM | 30004697 | ||
| MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay, GI50=2.97μM | 30004697 | ||
| BL21 (DE3) | Function assay | Binding affinity to human His-thioredoxin-tagged HDAC8 expressed in Escherichia coli BL21 (DE3) cells by ITC method, Kd=0.0751μM | 30347148 | |||
| BL21 (DE3) | Function assay | Inhibition of human His-thioredoxin-tagged HDAC8 expressed in Escherichia coli BL21 (DE3) cells using Fluor de Lys (R)-HDAC8 as substrate by fluorometric method, IC50=0.0777μM | 30347148 | |||
| BL21 (DE3) | Function assay | Binding affinity to Schistosoma mansoni His-tagged HDAC8 expressed in Escherichia coli BL21 (DE3) cells by ITC method, Kd=0.367μM | 30347148 | |||
| BL21 (DE3) | Function assay | Inhibition of Schistosoma mansoni His-tagged HDAC8 expressed in Escherichia coli BL21 (DE3) cells using Fluor de Lys (R)-HDAC8 as substrate by fluorometric method, IC50=0.4358μM | 30347148 | |||
| BL21 (DE3) | Function assay | Inhibition of human His-thioredoxin-tagged HDAC8 mL6/L179I mutant expressed in Escherichia coli BL21 (DE3) cells using Fluor de Lys (R)-HDAC8 as substrate by fluorometric method, IC50=1μM | 30347148 | |||
| BL21 (DE3) | Function assay | Inhibition of human His-thioredoxin-tagged HDAC8 mL6 mutant expressed in Escherichia coli BL21 (DE3) cells using Fluor de Lys (R)-HDAC8 as substrate by fluorometric method, IC50=1.63μM | 30347148 | |||
| BL21 (DE3) | Function assay | Inhibition of human His-thioredoxin-tagged HDAC8 mL1/mL6 mutant expressed in Escherichia coli BL21 (DE3) cells using Fluor de Lys (R)-HDAC8 as substrate by fluorometric method, IC50=2.7μM | 30347148 | |||
| BL21 (DE3) | Function assay | Inhibition of human His-thioredoxin-tagged HDAC8 mL1/mL6/L179I mutant expressed in Escherichia coli BL21 (DE3) cells using Fluor de Lys (R)-HDAC8 as substrate by fluorometric method, IC50=5μM | 30347148 | |||
| Sf9 | Function assay | Inhibition of C-terminal FLAG/His-tagged full length human HDAC1 expressed in baculovirus infected Sf9 insect cells using Z(Ac)Lys-AMC as substrate by fluorometric method, IC50=28.3μM | 30347148 | |||
| Sf9 | Function assay | Inhibition of N-terminal GST-tagged full length human HDAC6 expressed in baculovirus infected Sf9 insect cells using Z(Ac)Lys-AMC as substrate by fluorometric method, IC50=48.2μM | 30347148 | |||
| Sf9 | Function assay | 40 mins | Inhibition of recombinant human full length C-terminal His-tagged HDAC8 expressed in baculovirus infected insect cells measured after 40 mins by HDAC-Glo1/2 luminescent assay, IC50=0.03162μM | 30964290 | ||
| SK-N-BE(2)C | Anticlonogenic assay | 96 hrs | Anticlonogenic activity in human SK-N-BE(2)C cells assessed as reduction in cell proliferation incubated for 96 hrs by crystal violet staining based assay, GI50=15μM | 31630054 | ||
| Haga clic para ver más datos experimentales de líneas celulares | ||||||
| Peso molecular | 296.32 | Fórmula | C17H16N2O3 |
Almacenamiento (Desde la fecha de recepción) | |
|---|---|---|---|---|---|
| Nº CAS | 950762-95-5 | Descargar SDF | Almacenamiento de soluciones madre |
|
|
| Sinónimos | N/A | Smiles | COC1=CC=C(C=C1)CN2C=CC3=C2C=C(C=C3)C(=O)NO | ||
|
In vitro |
DMSO
: 59 mg/mL
(199.1 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)
Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)
Resultados del cálculo:
Concentración de trabajo: mg/ml;
Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH2O, mezclar y clarificar.
Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.
Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.
| Targets/IC50/Ki |
HDAC8
(Cell-free assay) 10 nM
|
|---|---|
| In vitro |
PCI-34051 posee una potencia prometedora para HDAC8 con un Ki de 10 nM. Este compuesto tiene una alta selectividad (aproximadamente cinco veces) para HDAC8 en relación con otras HDACs de clase I, incluida HDAC1. Revela una selectividad superior a 200 veces sobre HDAC1 y HDAC6, y superior a 1000 veces sobre HDAC2, HDAC3 y HDAC10. Este químico inhibe la línea tumoral ovárica OVCAR-3 con un GI50 de 6 μM y 15% de muerte celular. No se observa acetilación significativa de tubulina ni de histonas en las líneas celulares sensibles tratadas con este compuesto a concentraciones inferiores a 25 μM a las 24 horas ni en puntos temporales anteriores. Induce un efecto citotóxico selectivo solo en líneas celulares derivadas de neoplasias malignas de células T. Este compuesto induce apoptosis dependiente de caspasas. Cuando se mide la actividad de la caspasa-3 en varios momentos después del tratamiento con 5 μM de este químico, se observan niveles crecientes de actividad de 12 a 24 a 48 horas, otra característica de la apoptosis, consistente con los niveles más altos de actividad de la caspasa en este punto temporal. No estimula la escisión de Bid, un efecto característico de la vía apoptótica extrínseca. Mientras que P116 y J.RT3-T.5 son sensibles a este compuesto, la línea J.gamma1 deficiente en PLCγ1 revela una marcada disminución en la extensión de su apoptosis inducida. Además, los niveles de calcio en estado estacionario influyen fuertemente en la apoptosis inducida por este químico. Induce la liberación de citocromo c de las mitocondrias. |
| Ensayo de quinasa |
Actividad de histona desacetilasa
|
|
Para la caracterización de PCI-34051, las mediciones se realizan en un volumen de reacción de 100 μL utilizando placas de ensayo de 96 pocillos en un lector de placas de fluorescencia. Para cada isoenzima. La proteína HDAC en tampón de reacción (50 mM HEPES, 100 mM KCl, 0,001% Tween-20, 5% dimetil sulfóxido, pH 7,4, suplementado con albúmina sérica bovina en concentraciones de 0-0,05%) se mezcla con este compuesto a varias concentraciones y se deja incubar durante 15 min. Se añade tripsina a una concentración final de 50 nM, y acetil-glicil-Ala-(N-acetil-Lis)-amino-4-metilcoumarina se añade a una concentración final de 25-100 μM para iniciar la reacción. Después de un tiempo de latencia de 30 min, la fluorescencia se mide durante un período de 30 min utilizando una longitud de onda de excitación de 335 nm y una longitud de onda de detección de 460 nm. El aumento de la fluorescencia con el tiempo se utiliza como medida de la velocidad de reacción.
|
|
| In vivo |
PCI-34051 es un potente y específico inhibidor de HDAC8. |
Referencias |
|
| Métodos | Biomarcadores | Imágenes | PMID |
|---|---|---|---|
| Immunofluorescence | SMC3 / Ac-SMC3 |
|
27072133 |
Tel: +1-832-582-8158 Ext:3
Si tiene alguna otra consulta, por favor deje un mensaje.